First-line nivolumab plus ipilimumab or chemotherapy versus chemotherapy alone in advanced esophageal squamous cell carcinoma: a Japanese subgroup analysis of open-label, phase 3 trial (CheckMate 648/ONO-4538-50)

[1]  Qi Li,et al.  Toripalimab plus chemotherapy in treatment-naïve, advanced esophageal squamous cell carcinoma (JUPITER-06): A multi-center phase 3 trial. , 2022, Cancer cell.

[2]  J. Ajani,et al.  Nivolumab Combination Therapy in Advanced Esophageal Squamous-Cell Carcinoma. , 2022, The New England journal of medicine.

[3]  Jinchul Kim,et al.  Association of Smoking Status with Efficacy of First-line Immune Checkpoint Inhibitors in Advanced Non-small Cell Lung Cancers: A Systematic Review and Meta-analysis , 2022, Journal of Cancer.

[4]  R. Ishihara,et al.  Second-line pembrolizumab versus chemotherapy in Japanese patients with advanced esophageal cancer: subgroup analysis from KEYNOTE-181 , 2021, Esophagus.

[5]  Ying Cheng,et al.  Effect of Camrelizumab vs Placebo Added to Chemotherapy on Survival and Progression-Free Survival in Patients With Advanced or Metastatic Esophageal Squamous Cell Carcinoma: The ESCORT-1st Randomized Clinical Trial. , 2021, JAMA.

[6]  Y. Wang,et al.  LBA52 Sintilimab plus chemotherapy versus chemotherapy as first-line therapy in patients with advanced or metastatic esophageal squamous cell cancer: First results of the phase III ORIENT-15 study , 2021, Annals of Oncology.

[7]  Sung-Bae Kim,et al.  Pembrolizumab plus chemotherapy versus chemotherapy alone for first-line treatment of advanced oesophageal cancer (KEYNOTE-590): a randomised, placebo-controlled, phase 3 study , 2021, The Lancet.

[8]  Y. Doki,et al.  Nivolumab versus chemotherapy in Japanese patients with advanced esophageal squamous cell carcinoma: a subgroup analysis of a multicenter, randomized, open-label, phase 3 trial (ATTRACTION-3) , 2020, Esophagus.

[9]  T. Akimoto,et al.  Improved efficacy of taxanes and ramucirumab combination chemotherapy after exposure to anti-PD-1 therapy in advanced gastric cancer , 2020, ESMO open.

[10]  J. Ferlay,et al.  Global burden of oesophageal and gastric cancer by histology and subsite in 2018 , 2020, Gut.

[11]  K. Muro,et al.  Efficacy of Cytotoxic Agents After Progression on Anti-PD-(L)1 Antibody for Pre-treated Metastatic Gastric Cancer , 2020, AntiCancer Research.

[12]  Lei Dong,et al.  Smokers or non-smokers: who benefits more from immune checkpoint inhibitors in treatment of malignancies? An up-to-date meta-analysis , 2020, World journal of surgical oncology.

[13]  L. Urban,et al.  Nivolumab Plus Low-Dose IPILIMUMAB as First-Line Treatment of Advanced NSCLC: Overall Survival Analysis of Checkmate 817 , 2019 .

[14]  R. Motzer,et al.  Nivolumab plus ipilimumab versus sunitinib in previously untreated advanced renal-cell carcinoma: analysis of Japanese patients in CheckMate 214 with extended follow-up , 2019, Japanese journal of clinical oncology.

[15]  C. Porta,et al.  Nivolumab plus ipilimumab versus sunitinib in first-line treatment for advanced renal cell carcinoma: extended follow-up of efficacy and safety results from a randomised, controlled, phase 3 trial. , 2019, The Lancet. Oncology.

[16]  Sung-Bae Kim,et al.  Nivolumab versus chemotherapy in patients with advanced oesophageal squamous cell carcinoma refractory or intolerant to previous chemotherapy (ATTRACTION-3): a multicentre, randomised, open-label, phase 3 trial. , 2019, The Lancet. Oncology.

[17]  K. Syrigos,et al.  Nivolumab plus Ipilimumab in Advanced Non-Small-Cell Lung Cancer. , 2019, The New England journal of medicine.

[18]  Jun Yu Li,et al.  Pan-Asian adapted ESMO Clinical Practice Guidelines for the management of patients with metastatic oesophageal cancer: a JSMO–ESMO initiative endorsed by CSCO, KSMO, MOS, SSO and TOS , 2019, Annals of oncology : official journal of the European Society for Medical Oncology.

[19]  Masahiro Yoshida,et al.  Esophageal cancer practice guidelines 2017 edited by the Japan Esophageal Society: part 1 , 2018, Esophagus.

[20]  A. Costantini,et al.  Increased Response Rates to Salvage Chemotherapy Administered after PD-1/PD-L1 Inhibitors in Patients with Non-Small Cell Lung Cancer. , 2018, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[21]  Ken Kato,et al.  A retrospective analysis of 5-fluorouracil plus cisplatin as first-line chemotherapy in the recent treatment strategy for patients with metastatic or recurrent esophageal squamous cell carcinoma , 2018, International Journal of Clinical Oncology.